» Articles » PMID: 38783290

The Interleukin-6 Gene Variants May Protect Against SARS-CoV-2 Infection and the Severity of COVID-19: a Case-control Study in a Moroccan Population

Abstract

The symptoms of SARS-CoV-2 infection vary widely, ranging from asymptomatic cases to severe forms marked by acute respiratory distress syndrome, multi-organ damage, and fatalities. Studies indicate a correlation between specific genes and susceptibility to SARS-CoV-2 infection and disease severity, particularly involving variants in genes linked to inflammation and immune responses. The objective of this study is to investigate the association between rs1800795 (- 174 G > C) and rs1800797 (- 597 A > G) variants in the interleukin-6 (IL-6) promoter region and susceptibility to SARS-CoV-2 infection. Additionally, we aim to explore their correlation with COVID-19 severity in a Moroccan population. In this case-control study, we enrolled 270 unvaccinated COVID-19 patients, consisting of 132 with severe COVID-19 and 138 with asymptomatic-moderate COVID-19. Additionally, we included 339 SARS-CoV-2-negative group. Genotyping of rs1800795 and rs1800797 polymorphisms of the IL-6 gene was performed using predesigned TaqMan SNP genotyping. The median age of SARS-CoV-2-negative controls was 50 years, while severe COVID-19 cases exhibited a median age of 61 years. Additionally, individuals with asymptomatic to moderate COVID-19 had a median age of 36 years. We observed a significant age difference between severe and mild COVID-19 patients (p < 0.0001), and an association was noted between gender and the severity of COVID-19 (p = 0.011). The allele and genotype frequencies of the IL-6 - 597G > A and - 174G > C variants did not show significant associations with susceptibility to SARS-CoV-2 infection (p > 0.05). However, further analysis revealed that the linkage disequilibrium between rs1800797 and rs1800795 indicated that individuals with the GC* haplotype (OR = 0.04, 95% CI 0.01-0.30, p = 0.001) and AG* haplotype (OR = 0.11, 95% CI 0.03-0.46, p = 0.002) were significantly associated with protection against SARS-CoV-2 infection. Moreover, in the overdominant model, the IL-6 - 174 G/C genotype was found to be protective against the development of severe disease compared to those with the G/G-C/C genotypes (p = 0.03; OR = 0.41, 95% CI 0.18-0.96). However, correlations between complete blood count markers, hematological markers, D-dimer, C-reactive protein, and ferritin levels according to - 597 A > G and - 174G > C genotypes showed no significant differences (all p > 0.05). Our findings provide valuable insights into the pathogenesis of COVID-19, suggesting that genetic variations at the IL-6 gene may contribute to the susceptibility to severe SARS-CoV-2 infection within the Moroccan population.

Citing Articles

Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.

Yu C, Wang W, Zhang Q, Jin Z Front Immunol. 2025; 16:1510770.

PMID: 39958350 PMC: 11825795. DOI: 10.3389/fimmu.2025.1510770.


Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.

Paranga T, Mitu I, Pavel-Tanasa M, Rosu M, Miftode I, Constantinescu D Int J Mol Sci. 2024; 25(21).

PMID: 39518964 PMC: 11547016. DOI: 10.3390/ijms252111411.

References
1.
Humphries S, Luong L, Ogg M, Hawe E, Miller G . The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001; 22(24):2243-52. DOI: 10.1053/euhj.2001.2678. View

2.
Kaidashev I, Shlykova O, Izmailova O, Torubara O, Yushchenko Y, Tyshkovska T . Host gene variability and SARS-CoV-2 infection: A review article. Heliyon. 2021; 7(8):e07863. PMC: 8382593. DOI: 10.1016/j.heliyon.2021.e07863. View

3.
Brull D, Montgomery H, Sanders J, Dhamrait S, Luong L, Rumley A . Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001; 21(9):1458-63. DOI: 10.1161/hq0901.094280. View

4.
Stoeger T, Nunes Amaral L . COVID-19 research risks ignoring important host genes due to pre-established research patterns. Elife. 2020; 9. PMC: 7685703. DOI: 10.7554/eLife.61981. View

5.
Kilpinen S, Hulkkonen J, Wang X, Hurme M . The promoter polymorphism of the interleukin-6 gene regulates interleukin-6 production in neonates but not in adults. Eur Cytokine Netw. 2001; 12(1):62-8. View